In an exclusive interview with The Fly, SWK Holdings (SWKH) CEO Winston Black talked about the company, its formal application to list its common stock on the Nasdaq, its recent acquisition of Enteris BioPharma, and much more. Here are some highlights:
SPECIALIZED LIFE SCIENCE, FINANCE COMPANY: Noting that SWK is a specialized life science focused, finance company, CEO Winston Black explained to The Fly that they "focus on commercial opportunities." SWK invests in those opportunities by either owning an asset and owning "the royalty streams that are produced by the sales of those products, which is 20% of business today," or by doing structured credit.
NASDAQ LISTING: Last week, the company announced the addition of two new board directors and submitted a formal application to list its common stock on the Nasdaq. Black sees the up listing as an "upgrade of quality of listing" and a way to expand the potential universe of investors as many "don't generally look at OTC listed Securities." "The board is anticipating that by upgrading the listing and expanding the potential range of investors evaluating SWK it would be good for the company shareholders," the executive added.
ENTERIS ACQUISITION: Earlier this month, SWK announced the acquisition of Enteris BioPharma. "We really like the pharmaceutical royalty market," explained the CEO, adding that he believes Enteris potentially gives the company its own platform to generate royalties. Additionally, Black pointed out that by bringing operations into SWK, it "improves SWK's standing" within the life science ecosystem. "There is a lot of synergy between the finance business and Enteris' operations," the executive said.
REMAINDER OF THE YEAR: Looking over the remainder of the year, SWK's Black acknowledged that there are "a lot of very interesting opportunities that we're currently working on," that include working with existing portfolio companies and also new partnerships.
GROWTH PROSPECTS: While SWK's Black expects the company to continue to grow in all fronts, in the near-term, the executive sees the company looking at transactions that bolster Enteris' platform. "As we are becoming more entrenched in life sciences by acquiring Enteris, we will continue to see more and more interesting opportunities for us to execute upon," he contended.
"Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. A more detailed version of this interview to follow.
For more on SWK Holdings click here.
For more on SWK’s listing on the Nasdaq click here.
For more on SWK’s acquisition of Enteris BioPharma click here.
For more on SWK’s events for the remainder of the year click here.
For more on SWK’s growth prospects click here.